A Phase I, Open-label and Single-dose Study to Evaluate the Pharmacokinetics and Safety of a Single 40 mg Oral Dose of ABL001 (Asciminib) in Subjects With Impaired Renal Function Compared to Matched Control Subjects With Normal Renal Function
Phase of Trial: Phase I
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Asciminib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 26 Nov 2018 Planned End Date changed from 4 Dec 2019 to 2 Jan 2020.
- 14 Oct 2018 Planned End Date changed from 20 Nov 2019 to 4 Dec 2019.
- 28 Sep 2018 Planned End Date changed from 12 Nov 2019 to 20 Nov 2019.